APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cannabinoid-based Antitumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cannabinoid-based Antitumor Drug Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchCannabinoid-based Antitumor Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Cannabinoid-based Antitumor Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Cannabinoid-based Antitumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cannabinoid-based Antitumor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cannabinoid-based Antitumor Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Cannabinoid-based Antitumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cannabinoid-based Antitumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cannabinoid-based Antitumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cannabinoid-based Antitumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cannabinoid-based Antitumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cannabinoid-based Antitumor Drug market include Cannabics Inc., GW Pharmaceuticals, Jay Pharma, Medicanja Ltd, Tikun Olam and Valeant Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cannabinoid-based Antitumor Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cannabinoid-based Antitumor Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cannabinoid-based Antitumor Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cannabinoid-based Antitumor Drug market.

Cannabinoid-based Antitumor Drug Segment by Company

Cannabics Inc.

GW Pharmaceuticals

Jay Pharma

Medicanja Ltd

Tikun Olam

Valeant Pharmaceuticals

Cannabinoid-based Antitumor Drug Segment by Type

Chewing Medicine

Lozenge

Other

Cannabinoid-based Antitumor Drug Segment by Application

Clinics

Hospitals

Others

Cannabinoid-based Antitumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cannabinoid-based Antitumor Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cannabinoid-based Antitumor Drug key companies, revenue, market share, and recent developments.

3. To split the Cannabinoid-based Antitumor Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cannabinoid-based Antitumor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cannabinoid-based Antitumor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Cannabinoid-based Antitumor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cannabinoid-based Antitumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cannabinoid-based Antitumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cannabinoid-based Antitumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cannabinoid-based Antitumor Drug industry.

Chapter 3: Detailed analysis of Cannabinoid-based Antitumor Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cannabinoid-based Antitumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cannabinoid-based Antitumor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cannabinoid-based Antitumor Drug Industry Trends Table 2. Cannabinoid-based Antitumor Drug Industry Drivers Table 3. Cannabinoid-based Antitumor Drug Industry Opportunities and Challenges Table 4. Cannabinoid-based Antitumor Drug Industry Restraints Table 5. Global Cannabinoid-based Antitumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cannabinoid-based Antitumor Drug Revenue Share by Company (2021-2026) Table 7. Global Cannabinoid-based Antitumor Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cannabinoid-based Antitumor Drug Key Company Manufacturing Base & Headquarters Table 9. Global Cannabinoid-based Antitumor Drug Company, Product Type & Application Table 10. Global Cannabinoid-based Antitumor Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cannabinoid-based Antitumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chewing Medicine Table 15. Significant Companies of Lozenge Table 16. Significant Companies of Other Table 17. Global Cannabinoid-based Antitumor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Cannabinoid-based Antitumor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Cannabinoid-based Antitumor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Cannabinoid-based Antitumor Drug Sales Value Share by Type (2021-2026) Table 21. Global Cannabinoid-based Antitumor Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Clinics Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Others Table 25. Global Cannabinoid-based Antitumor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Cannabinoid-based Antitumor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Cannabinoid-based Antitumor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Cannabinoid-based Antitumor Drug Sales Value Share by Application (2021-2026) Table 29. Global Cannabinoid-based Antitumor Drug Sales Value Share by Application (2027-2032) Table 30. Global Cannabinoid-based Antitumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Cannabinoid-based Antitumor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Cannabinoid-based Antitumor Drug Sales Value Share by Region (2021-2026) Table 33. Global Cannabinoid-based Antitumor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Cannabinoid-based Antitumor Drug Sales Value Share by Region (2027-2032) Table 35. Global Cannabinoid-based Antitumor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Cannabinoid-based Antitumor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Cannabinoid-based Antitumor Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Cannabinoid-based Antitumor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Cannabinoid-based Antitumor Drug Sales Value Market Share by Country (2027-2032) Table 40. Cannabics Inc. Company Information Table 41. Cannabics Inc. Business Overview Table 42. Cannabics Inc. Cannabinoid-based Antitumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Cannabics Inc. Cannabinoid-based Antitumor Drug Product Portfolio Table 44. Cannabics Inc. Recent Development Table 45. GW Pharmaceuticals Company Information Table 46. GW Pharmaceuticals Business Overview Table 47. GW Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GW Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio Table 49. GW Pharmaceuticals Recent Development Table 50. Jay Pharma Company Information Table 51. Jay Pharma Business Overview Table 52. Jay Pharma Cannabinoid-based Antitumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Jay Pharma Cannabinoid-based Antitumor Drug Product Portfolio Table 54. Jay Pharma Recent Development Table 55. Medicanja Ltd Company Information Table 56. Medicanja Ltd Business Overview Table 57. Medicanja Ltd Cannabinoid-based Antitumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Medicanja Ltd Cannabinoid-based Antitumor Drug Product Portfolio Table 59. Medicanja Ltd Recent Development Table 60. Tikun Olam Company Information Table 61. Tikun Olam Business Overview Table 62. Tikun Olam Cannabinoid-based Antitumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Tikun Olam Cannabinoid-based Antitumor Drug Product Portfolio Table 64. Tikun Olam Recent Development Table 65. Valeant Pharmaceuticals Company Information Table 66. Valeant Pharmaceuticals Business Overview Table 67. Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio Table 69. Valeant Pharmaceuticals Recent Development Table 70. Research Programs/Design for This Report Table 71. Authors List of This Report Table 72. Secondary Sources Table 73. Primary Sources List of Figures Figure 1. Cannabinoid-based Antitumor Drug Product Image Figure 2. Global Cannabinoid-based Antitumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cannabinoid-based Antitumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Cannabinoid-based Antitumor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chewing Medicine Image Figure 8. Lozenge Image Figure 9. Other Image Figure 10. Global Cannabinoid-based Antitumor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Cannabinoid-based Antitumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Cannabinoid-based Antitumor Drug Sales Value Share by Type (2021-2032) Figure 13. Clinics Image Figure 14. Hospitals Image Figure 15. Others Image Figure 16. Global Cannabinoid-based Antitumor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cannabinoid-based Antitumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cannabinoid-based Antitumor Drug Sales Value Share by Application (2021-2032) Figure 19. Global Cannabinoid-based Antitumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Cannabinoid-based Antitumor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Cannabinoid-based Antitumor Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Cannabinoid-based Antitumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Cannabinoid-based Antitumor Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Cannabinoid-based Antitumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Cannabinoid-based Antitumor Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Cannabinoid-based Antitumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Cannabinoid-based Antitumor Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Cannabinoid-based Antitumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Cannabinoid-based Antitumor Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Cannabinoid-based Antitumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Chewing Medicine
  • Lozenge
  • Other
Applications
  • Clinics
  • Hospitals
  • Others
Companies covered
  • Cannabics Inc.
  • GW Pharmaceuticals
  • Jay Pharma
  • Medicanja Ltd
  • Tikun Olam
  • Valeant Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cannabinoid-based Antitumor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cannabinoid-based Antitumor Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cannabinoid-based Antitumor Drug Market Dynamics
  1. 2.1 Cannabinoid-based Antitumor Drug Industry Trends
  2. 2.2 Cannabinoid-based Antitumor Drug Industry Drivers
  3. 2.3 Cannabinoid-based Antitumor Drug Industry Opportunities and Challenges
  4. 2.4 Cannabinoid-based Antitumor Drug Industry Restraints
3 Cannabinoid-based Antitumor Drug Market by Company
  1. 3.1 Global Cannabinoid-based Antitumor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Cannabinoid-based Antitumor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Cannabinoid-based Antitumor Drug Company Ranking (2024-2026)
  4. 3.4 Global Cannabinoid-based Antitumor Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Cannabinoid-based Antitumor Drug Company Product Type and Application
  6. 3.6 Global Cannabinoid-based Antitumor Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cannabinoid-based Antitumor Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cannabinoid-based Antitumor Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cannabinoid-based Antitumor Drug Market by Type
  1. 4.1 Cannabinoid-based Antitumor Drug Type Introduction
  2. 4.1.1 Chewing Medicine
  3. 4.1.2 Lozenge
  4. 4.1.3 Other
  5. 4.2 Global Cannabinoid-based Antitumor Drug Sales Value by Type
  6. 4.2.1 Global Cannabinoid-based Antitumor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Cannabinoid-based Antitumor Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Cannabinoid-based Antitumor Drug Sales Value Share by Type (2021-2032)
5 Cannabinoid-based Antitumor Drug Market by Application
  1. 5.1 Cannabinoid-based Antitumor Drug Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Others
  5. 5.2 Global Cannabinoid-based Antitumor Drug Sales Value by Application
  6. 5.2.1 Global Cannabinoid-based Antitumor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cannabinoid-based Antitumor Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Cannabinoid-based Antitumor Drug Sales Value Share by Application (2021-2032)
6 Cannabinoid-based Antitumor Drug Regional Value Analysis
  1. 6.1 Global Cannabinoid-based Antitumor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cannabinoid-based Antitumor Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cannabinoid-based Antitumor Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cannabinoid-based Antitumor Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cannabinoid-based Antitumor Drug Sales Value (2021-2032)
  7. 6.3.2 North America Cannabinoid-based Antitumor Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cannabinoid-based Antitumor Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Cannabinoid-based Antitumor Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cannabinoid-based Antitumor Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cannabinoid-based Antitumor Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cannabinoid-based Antitumor Drug Sales Value (2021-2032)
  16. 6.6.2 South America Cannabinoid-based Antitumor Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cannabinoid-based Antitumor Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cannabinoid-based Antitumor Drug Sales Value Share by Country, 2025 VS 2032
7 Cannabinoid-based Antitumor Drug Country-level Value Analysis
  1. 7.1 Global Cannabinoid-based Antitumor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cannabinoid-based Antitumor Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cannabinoid-based Antitumor Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cannabinoid-based Antitumor Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cannabinoid-based Antitumor Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cannabinoid-based Antitumor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cannabinoid-based Antitumor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cannabics Inc.
  2. 8.1.1 Cannabics Inc. Company Information
  3. 8.1.2 Cannabics Inc. Business Overview
  4. 8.1.3 Cannabics Inc. Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cannabics Inc. Cannabinoid-based Antitumor Drug Product Portfolio
  6. 8.1.5 Cannabics Inc. Recent Developments
  7. 8.2 GW Pharmaceuticals
  8. 8.2.1 GW Pharmaceuticals Company Information
  9. 8.2.2 GW Pharmaceuticals Business Overview
  10. 8.2.3 GW Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GW Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio
  12. 8.2.5 GW Pharmaceuticals Recent Developments
  13. 8.3 Jay Pharma
  14. 8.3.1 Jay Pharma Company Information
  15. 8.3.2 Jay Pharma Business Overview
  16. 8.3.3 Jay Pharma Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jay Pharma Cannabinoid-based Antitumor Drug Product Portfolio
  18. 8.3.5 Jay Pharma Recent Developments
  19. 8.4 Medicanja Ltd
  20. 8.4.1 Medicanja Ltd Company Information
  21. 8.4.2 Medicanja Ltd Business Overview
  22. 8.4.3 Medicanja Ltd Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Medicanja Ltd Cannabinoid-based Antitumor Drug Product Portfolio
  24. 8.4.5 Medicanja Ltd Recent Developments
  25. 8.5 Tikun Olam
  26. 8.5.1 Tikun Olam Company Information
  27. 8.5.2 Tikun Olam Business Overview
  28. 8.5.3 Tikun Olam Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tikun Olam Cannabinoid-based Antitumor Drug Product Portfolio
  30. 8.5.5 Tikun Olam Recent Developments
  31. 8.6 Valeant Pharmaceuticals
  32. 8.6.1 Valeant Pharmaceuticals Company Information
  33. 8.6.2 Valeant Pharmaceuticals Business Overview
  34. 8.6.3 Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio
  36. 8.6.5 Valeant Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst